NeuTherapeutics

Executive Summary

NeuTherapeutics is a private, Nashville-based biotech founded in 2017, advancing regenerative treatments for neurodegenerative diseases and precision therapies for women's brain health. The company employs a patient-centric, data-driven approach, bridging scientific discovery to clinical cures. Currently in Phase 2, NeuTherapeutics is developing candidate drugs targeting unmet needs in conditions like Alzheimer's, Parkinson's, and menopause-related cognitive decline, leveraging small molecule platforms. Its focus on women's brain health is a differentiating factor in a market traditionally dominated by generalized neurodegeneration approaches. The company's pipeline, though not publicly detailed, is poised to deliver key clinical readouts that could validate its technology and drive significant value creation. With a lean structure and a clear therapeutic focus, NeuTherapeutics represents a high-upside opportunity in the neuroscience space, albeit with typical development-stage risks.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data for lead candidate in Alzheimer's disease60% success
• Q2 2026Strategic partnership for women's brain health program (e.g., menopause-related cognitive decline)50% success
• Q4 2026Series B financing to advance pipeline70% success